[Downloaded free from http://www.eusjournal.com on Monday, March 06, 2017, IP: 147.140.233.17]

Editorial

Can contrast harmonic endoscopic ultrasonography
replace endoscopic ultrasonography‑guided fine‑needle
aspiration in patients with solid pancreatic lesions? An
American perspective
Joseph Yoo, Linda H. Yan, Ali A. Siddiqui
Department of Internal Medicine, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital,
Philadelphia, PA, USA

INTRODUCTION
Contrast har monic endoscopic ultrasonography
(CH‑EUS) is a novel for m of endoscopic
ultrasonography (EUS) that utilizes intravenous contrast
agents to characterize the vasculature inside an organ
of interest with a broadband transducer that can
detect harmonic signals. [1,2] These contrast agents
initially played a major role in echocardiography,
enhancing the power of ultrasonography to image
cardiac chambers and the nearby large blood vessels.[3]
They have been since utilized with EUS to aid clinicians
in differentiating between benign and malignant lesions,
in determining the depth of esophageal, gastric, and
gallbladder cancer invasion, and in imaging the portal
venous system and varices. [2] Contrast agents are
especially important in tumor imaging because tumor
angiogenesis usually significantly alters the vasculature
within the malignant lesion. The intravenous contrast
agents are typically administered via an intravenous
bolus injection of gaseous microbubbles that do not
leave the vascular system and reflect the ultrasound
waves. The contrast can also be injected as a
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continuous infusion, which can alter the appearance
of vasculature on CH‑EUS due to the difference in
intravascular density of the contrast material.
In the USA, accurately diagnosing solid lesions of the
pancreas remains an area of ongoing study because
it has significant therapeutic implications. Pancreatic
ductal adenocarcinoma, the most common solid
pancreatic tumor, has a very poor prognosis and
often requires early surgical intervention to prevent
rapid progression. Conversely, neuroendocrine tumors
have a much slower rate of progression and do not
typically require immediate surgical intervention.
Inflammatory masses associated with chronic
pancreatitis also usually do not require surgery and
can be managed conservatively. CH‑EUS has been
proposed as an important imaging modality that can
aid in distinguishing between the different types of
pancreatic lesions, thereby potentially sparing patients
from the high morbidity and mortality associated with
pancreatic surgery.[4]
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CONTRAST HARMONIC ENDOSCOPIC
ULTRASONOGRAPHY: CURRENT DATA
The current gold standard for the diagnosis of
malignant pancreatic lesions, and for the differentiation
between pancreatic tumors and chronic pancreatitis, is
EUS‑guided fine‑needle aspiration (EUS‑FNA).[5] It has
been well established in the literature that differentiating
between pancreatic masses caused by inflammation
and carcinoma can be challenging. Despite the fact
that histopathologic evaluation is the gold standard for
diagnosing pancreatic masses, it is not always accurate,
as many carcinomas are surrounded by inflammatory
changes. The surrounding inflammation has been shown
to result in false‑negative results, even when the tissue
is obtained via EUS‑FNA.[6] As such, clinicians have
continued to search for the best method for diagnosing
pancreatic masses.
CH‑EUS has been shown to be useful in pancreatic
imaging by defining vascular landmarks, identifying
the obliteration of vasculature by a thrombus or
tumor, and by deter mining microvascular blood
flow in the pancreas and pancreatic lesions. Current
literature suggests that the degree of enhancement
with contrast agents may be related to the amount
of microcirculation and vascular permeability within a
pancreatic lesion or to the degree of inflammation in
pancreatic parenchyma.[7‑11]
Normal pancreatic parenchyma and the areas of fibrosis
typically enhance with contrast, while the appearance
of pancreatic masses with CH‑EUS depends on
the cytopathology of the lesion. [7,8] Pancreatic islet
cell tumors and mucin‑producing tumors typically
have marked enhancement with contrast utilization,
while pancreatic ductal cell carcinomas and pancreatic
pseudocysts typically remain unenhanced due to their
relative avascularity.[1] Hirooka et al. demonstrated that
these findings were consistent with the vascularity
demonstrated by angiography except in 20% of the
cases of mucin‑producing tumors and in 25% of the
cases of chronic pancreatitis.[1,7] They also indicated
that the boundaries of normal pancreatic parenchyma
and fibrosis can be enhanced with contrast, helping
to further delineate the pancreatic lesions. [7,8] In
addition, CH‑EUS can be used to differentiate between
mass‑forming chronic pancreatitis and pancreatic cancer.
Dietrich et al. demonstrated that the difference in
tissue microperfusion between chronic pancreatitis and
pancreatic cancer results in differences in appearance
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on CH‑EUS.[10] Whereas focal lesions due to chronic
pancreatitis enhance inversely proportional to the
degree of fibrosis and duration of inflammation within
the mass, ductal carcinomas displayed a low level, or
complete absence of enhancement, due to the relatively
greater degree of fibrosis.[1,10,12,13]
Taking advantage of the different appearances of
varying pancreatic mass lesions on CH‑EUS has been
shown to be quite effective in several studies in the
international community. Based on the meta‑analysis
by Gong et al., CH‑EUS has a great potential for
differentiating pancreatic adenocarcinomas from other
pancreatic masses, with a sensitivity of 94% (95%
confidence interval [CI], 0.91–0.95) and a specificity
of 89% (95% CI, 0.85–0.92). [14] In fact, multiple
studies have shown that the negative predictive value
for the diagnosis of adenocarcinoma in pancreatic
masses is greater with CH‑EUS than with EUS‑FNA,
and that CH‑EUS is more sensitive if not more than
EUS‑FNA.[15,16]
AN AMERICAN PERSPECTIVE
As previously discussed, multiple studies have
demonstrated the advantages of using contrast‑enhanced
endoscopic ultrasound in the diagnosis of pancreatic
mass lesions. The majority of these studies, however,
continue to be primarily from Europe and Asia.
In fact, the European Federation of Societies for
Ultrasound in Medicine and Biology has already
released updated clinical guidelines regarding the use of
contrast‑enhanced endoscopic ultrasound, with sections
pertaining specifically to the pancreas.[17]
One of the earliest investigations into the potential
of contrast‑enhanced endoscopic ultrasound in North
America was published by Bhutani et al. in 1997. [18]
These early experiments, performed on three 20–25 kg
swine (Sus scrofa), demonstrated visually noticeable
enhancement of the color Doppler signals from the
celiac and superior mesenteric arteries after injections
of SHU508 (Levovist). Based on their findings,
Bhutani et al. hypothesized that vascular contrast agents
had the potential to have a significant role in improving
the diagnostic accuracy of pancreatic masses, as the
celiac and superior mesenteric arteries serve as the two
main sources of blood supply to the pancreas.[18] Since
these early experiments, however, the relative majority
of studies utilizing contrast‑enhanced endoscopic
ultrasound have come from Europe and Asia.
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In the previously mentioned meta‑analysis
by Gong et al., only one of the studies included
was perfor med in the USA. [14] The results of
that study, by Romagnuolo et al., revealed a
positive/negative predictive value of 80.0% (95% CI,
51.9%–95.7%)/100.0% (95% CI, 63.0%–100.0%) for
contrast‑enhanced harmonic EUS versus 84.6%/100.0%
for EUS in 24 cases with confir med diagnoses
(12 malignant and 12 benign).[19] The conclusions from
that study were consistent with the conclusions of the
international community thus far; contrast‑enhanced
endoscopic ultrasound is safe, time‑efficient,
cost‑conscious, and effective in the evaluation and
diagnosis of pancreatic mass lesions when compared to
the gold standard EUS‑FNA. Unfortunately, publishing
more American‑based studies has proven to be difficult
given the regulatory barriers that have been put in place
by the Food and Drug Administration (FDA).[18] Not
only the use of ultrasound contrast agents has not been
approved in the setting of endoscopic ultrasound, but
also black‑box warnings and contraindications issued by
the FDA make it necessary to exercise a considerable
amount of caution.
Currently, more studies need to be conducted in
American centers before one can form a unique
American perspective regarding the potential of
CH‑EUS to replace EUS‑FNA. EUS‑FNA is the
current gold standard, and as such, has been proven
to be an effective method by which to diagnose solid
pancreatic tumors and to differentiate malignancy from
chronic pancreatitis. However, the aforementioned
risk of obtaining falsely negative histopathology due
to sampling tissue from the areas of surrounding
inflammation as opposed to areas with malignant
changes remains a major concern. One can argue that
it is in these settings that CH‑EUS has its greatest
utility, not as a substitute to EUS‑FNA, but as a
complementary modality that can increase the diagnostic
accuracy of EUS‑FNA by identifying hypoenhancing
regions to target for sampling. Furthermore, data
released by Fusaroli and Eloubeidi and Gincul
et al. have already lent support to this notion. [20-22]
Nevertheless, the final verdict regarding the role
of CH‑EUS, whether it acts as a complement or
replacement, remains to be seen. From an American
perspective, the first step toward obtaining the answer
requires a regulatory shift toward more reasonable
limitations pertaining to the use of contrast‑enhancing
agents so that further studies can be done.
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